HK Stock MarketDetailed Quotes

01099 SINOPHARM

Watchlist
  • 20.250
  • +0.630+3.21%
Market Closed May 6 16:08 CST
63.19BMarket Cap6.45P/E (TTM)

SINOPHARM Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
(Q3)Mar 31, 2022
(FY)Dec 31, 2021
Turnover
1.20%147.27B
8.05%596.57B
9.73%445.92B
15.10%300.95B
14.04%145.52B
5.97%552.15B
6.58%406.38B
4.96%261.47B
6.10%127.6B
14.16%521.05B
Operating income
1.20%147.27B
8.05%596.57B
9.73%445.92B
15.10%300.95B
14.04%145.52B
5.97%552.15B
6.58%406.38B
4.96%261.47B
6.10%127.6B
14.16%521.05B
Cost of sales
----
-8.59%-548.06B
----
-15.79%-277.68B
----
-5.81%-504.71B
----
-4.94%-239.81B
----
-14.64%-477B
Operating expenses
-1.57%-136.69B
-8.59%-548.06B
-10.31%-410.72B
-15.79%-277.68B
-14.45%-134.58B
-5.81%-504.71B
-6.74%-372.34B
-4.94%-239.81B
-5.89%-117.59B
-14.64%-477B
Gross profit
-3.34%10.58B
2.27%48.51B
3.38%35.2B
7.45%23.27B
9.30%10.94B
7.68%47.43B
4.85%34.05B
5.20%21.66B
8.58%10.01B
9.24%44.05B
Selling expenses
-1.75%-4.21B
-4.50%-17.47B
-6.12%-12.65B
-8.44%-8.43B
-8.87%-4.13B
-8.30%-16.72B
-2.18%-11.92B
-2.26%-7.78B
-1.13%-3.8B
-9.16%-15.44B
Administrative expenses
-0.84%-1.75B
-6.04%-8.68B
-5.90%-5.48B
-8.43%-3.97B
-7.15%-1.74B
-5.44%-8.18B
-5.70%-5.18B
-6.33%-3.66B
-5.04%-1.62B
-10.09%-7.76B
Research and development expenses
25.87%-71.13M
----
-23.96%-260.77M
----
-55.73%-95.96M
----
-66.90%-210.37M
----
-45.83%-61.62M
----
Profit from asset sales
-85.73%3.33M
-6.80%-2.07B
1,278.98%322.01M
----
545.49%23.3M
-71.22%-1.94B
-52.87%23.35M
----
-91.67%3.61M
11.21%-1.13B
Revaluation surplus
135.67%20.9K
----
-101.34%-102.82K
----
-100.75%-58.58K
----
4,508,976.74%7.67M
----
31,179.01%7.76M
----
-Changes in the fair value of other assets
135.67%20.9K
----
-101.34%-102.82K
----
-100.75%-58.58K
----
4,508,976.74%7.67M
----
31,179.01%7.76M
----
Impairment and provision
-14.48%-901.55M
-0.07%-666.97M
-21.28%-1.62B
-30.58%-1.29B
-40.08%-787.55M
-11.36%-666.47M
-39.64%-1.34B
-38.99%-987.6M
-17.48%-562.2M
20.23%-598.48M
-Other impairment is provision
-14.48%-901.55M
-0.07%-666.97M
-21.28%-1.62B
-30.58%-1.29B
-40.08%-787.55M
-11.36%-666.47M
-39.64%-1.34B
-38.99%-987.6M
-17.48%-562.2M
20.23%-598.48M
Special items of operating profit
-27.35%213.15M
-13.92%582.01M
42.78%574.7M
101.04%1.82M
77.82%293.38M
14.76%676.16M
-33.62%402.52M
-205.35%-175.83M
-30.51%164.99M
-9.63%589.19M
Operating profit
-16.01%3.52B
-1.92%20.21B
1.56%15.07B
5.79%9.58B
9.36%4.19B
4.53%20.6B
2.03%14.84B
3.25%9.06B
12.30%3.84B
10.99%19.71B
Financing income
----
36.96%743.37M
----
9.77%350.3M
----
-2.83%542.77M
----
1.80%319.13M
----
-17.07%558.56M
Financing cost
23.68%-427.49M
14.98%-3.17B
10.00%-2.03B
7.11%-1.77B
18.79%-560.15M
5.77%-3.73B
3.26%-2.25B
-0.25%-1.9B
-8.60%-689.75M
-9.42%-3.96B
Share of profits of associates
----
4.46%1.11B
----
16.39%571.3M
----
-0.47%1.06B
----
8.04%490.85M
----
8.48%1.07B
Share of profit from joint venture company
----
-244.88%-4.22M
----
46.72%2.98M
----
318.99%2.91M
----
239.87%2.03M
----
-63.44%695K
Special items of earning before tax
635.15%27.71M
660.80%625.97M
-2,740.26%-19.47M
236.55%128.2M
-14.76%3.77M
121.89%82.28M
-96.94%737.47K
-49.38%38.09M
-55.72%4.42M
-85.75%-375.81M
Earning before tax
-14.15%3.12B
5.11%19.51B
3.47%13.03B
10.77%8.87B
15.49%3.64B
9.18%18.56B
2.85%12.59B
3.72%8B
12.90%3.15B
9.01%17B
Tax
12.44%-724.85M
-6.73%-4.5B
-6.55%-2.96B
-11.14%-1.97B
-14.72%-827.84M
-7.11%-4.22B
-1.95%-2.78B
-5.13%-1.78B
-14.68%-721.61M
-12.50%-3.94B
After-tax profit from continuing operations
-14.65%2.4B
4.63%15.01B
2.60%10.07B
10.67%6.89B
15.72%2.81B
9.80%14.35B
3.10%9.81B
3.32%6.23B
12.38%2.43B
8.00%13.06B
Earning after tax
-14.65%2.4B
4.63%15.01B
2.60%10.07B
10.67%6.89B
15.72%2.81B
9.80%14.35B
3.10%9.81B
3.32%6.23B
12.38%2.43B
8.00%13.06B
Minority profit
-19.80%978.14M
2.34%5.96B
0.39%3.97B
10.02%2.79B
21.91%1.22B
9.68%5.82B
3.66%3.96B
3.65%2.53B
5.91%1B
8.07%5.31B
Adjustment items of profit attributable to shareholders
----
----
----
----
----
----
---0.01
----
----
----
Profit attributable to shareholders
-10.70%1.42B
6.19%9.05B
4.09%6.1B
11.12%4.1B
11.38%1.59B
9.89%8.53B
2.73%5.86B
3.10%3.69B
17.41%1.43B
7.95%7.76B
Basic earnings per share
-9.80%0.46
6.23%2.9
4.26%1.96
11.86%1.32
10.87%0.51
9.64%2.73
2.73%1.88
2.61%1.18
17.95%0.46
7.79%2.49
Diluted earnings per share
-9.80%0.46
6.23%2.9
4.26%1.96
11.86%1.32
10.87%0.51
9.64%2.73
2.73%1.88
2.61%1.18
17.95%0.46
7.79%2.49
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
Audit Opinions
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
Auditor
--
PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian (Special General Partnership)
--
--
--
Ernst & Young Huaming (Special General Partnership), Ernst & Young
--
--
--
Ernst & Young Huaming (Special General Partnership), Ernst & Young
(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022(Q3)Mar 31, 2022(FY)Dec 31, 2021
Turnover 1.20%147.27B8.05%596.57B9.73%445.92B15.10%300.95B14.04%145.52B5.97%552.15B6.58%406.38B4.96%261.47B6.10%127.6B14.16%521.05B
Operating income 1.20%147.27B8.05%596.57B9.73%445.92B15.10%300.95B14.04%145.52B5.97%552.15B6.58%406.38B4.96%261.47B6.10%127.6B14.16%521.05B
Cost of sales -----8.59%-548.06B-----15.79%-277.68B-----5.81%-504.71B-----4.94%-239.81B-----14.64%-477B
Operating expenses -1.57%-136.69B-8.59%-548.06B-10.31%-410.72B-15.79%-277.68B-14.45%-134.58B-5.81%-504.71B-6.74%-372.34B-4.94%-239.81B-5.89%-117.59B-14.64%-477B
Gross profit -3.34%10.58B2.27%48.51B3.38%35.2B7.45%23.27B9.30%10.94B7.68%47.43B4.85%34.05B5.20%21.66B8.58%10.01B9.24%44.05B
Selling expenses -1.75%-4.21B-4.50%-17.47B-6.12%-12.65B-8.44%-8.43B-8.87%-4.13B-8.30%-16.72B-2.18%-11.92B-2.26%-7.78B-1.13%-3.8B-9.16%-15.44B
Administrative expenses -0.84%-1.75B-6.04%-8.68B-5.90%-5.48B-8.43%-3.97B-7.15%-1.74B-5.44%-8.18B-5.70%-5.18B-6.33%-3.66B-5.04%-1.62B-10.09%-7.76B
Research and development expenses 25.87%-71.13M-----23.96%-260.77M-----55.73%-95.96M-----66.90%-210.37M-----45.83%-61.62M----
Profit from asset sales -85.73%3.33M-6.80%-2.07B1,278.98%322.01M----545.49%23.3M-71.22%-1.94B-52.87%23.35M-----91.67%3.61M11.21%-1.13B
Revaluation surplus 135.67%20.9K-----101.34%-102.82K-----100.75%-58.58K----4,508,976.74%7.67M----31,179.01%7.76M----
-Changes in the fair value of other assets 135.67%20.9K-----101.34%-102.82K-----100.75%-58.58K----4,508,976.74%7.67M----31,179.01%7.76M----
Impairment and provision -14.48%-901.55M-0.07%-666.97M-21.28%-1.62B-30.58%-1.29B-40.08%-787.55M-11.36%-666.47M-39.64%-1.34B-38.99%-987.6M-17.48%-562.2M20.23%-598.48M
-Other impairment is provision -14.48%-901.55M-0.07%-666.97M-21.28%-1.62B-30.58%-1.29B-40.08%-787.55M-11.36%-666.47M-39.64%-1.34B-38.99%-987.6M-17.48%-562.2M20.23%-598.48M
Special items of operating profit -27.35%213.15M-13.92%582.01M42.78%574.7M101.04%1.82M77.82%293.38M14.76%676.16M-33.62%402.52M-205.35%-175.83M-30.51%164.99M-9.63%589.19M
Operating profit -16.01%3.52B-1.92%20.21B1.56%15.07B5.79%9.58B9.36%4.19B4.53%20.6B2.03%14.84B3.25%9.06B12.30%3.84B10.99%19.71B
Financing income ----36.96%743.37M----9.77%350.3M-----2.83%542.77M----1.80%319.13M-----17.07%558.56M
Financing cost 23.68%-427.49M14.98%-3.17B10.00%-2.03B7.11%-1.77B18.79%-560.15M5.77%-3.73B3.26%-2.25B-0.25%-1.9B-8.60%-689.75M-9.42%-3.96B
Share of profits of associates ----4.46%1.11B----16.39%571.3M-----0.47%1.06B----8.04%490.85M----8.48%1.07B
Share of profit from joint venture company -----244.88%-4.22M----46.72%2.98M----318.99%2.91M----239.87%2.03M-----63.44%695K
Special items of earning before tax 635.15%27.71M660.80%625.97M-2,740.26%-19.47M236.55%128.2M-14.76%3.77M121.89%82.28M-96.94%737.47K-49.38%38.09M-55.72%4.42M-85.75%-375.81M
Earning before tax -14.15%3.12B5.11%19.51B3.47%13.03B10.77%8.87B15.49%3.64B9.18%18.56B2.85%12.59B3.72%8B12.90%3.15B9.01%17B
Tax 12.44%-724.85M-6.73%-4.5B-6.55%-2.96B-11.14%-1.97B-14.72%-827.84M-7.11%-4.22B-1.95%-2.78B-5.13%-1.78B-14.68%-721.61M-12.50%-3.94B
After-tax profit from continuing operations -14.65%2.4B4.63%15.01B2.60%10.07B10.67%6.89B15.72%2.81B9.80%14.35B3.10%9.81B3.32%6.23B12.38%2.43B8.00%13.06B
Earning after tax -14.65%2.4B4.63%15.01B2.60%10.07B10.67%6.89B15.72%2.81B9.80%14.35B3.10%9.81B3.32%6.23B12.38%2.43B8.00%13.06B
Minority profit -19.80%978.14M2.34%5.96B0.39%3.97B10.02%2.79B21.91%1.22B9.68%5.82B3.66%3.96B3.65%2.53B5.91%1B8.07%5.31B
Adjustment items of profit attributable to shareholders ---------------------------0.01------------
Profit attributable to shareholders -10.70%1.42B6.19%9.05B4.09%6.1B11.12%4.1B11.38%1.59B9.89%8.53B2.73%5.86B3.10%3.69B17.41%1.43B7.95%7.76B
Basic earnings per share -9.80%0.466.23%2.94.26%1.9611.86%1.3210.87%0.519.64%2.732.73%1.882.61%1.1817.95%0.467.79%2.49
Diluted earnings per share -9.80%0.466.23%2.94.26%1.9611.86%1.3210.87%0.519.64%2.732.73%1.882.61%1.1817.95%0.467.79%2.49
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKAS
Audit Opinions --Unqualified Opinion------Unqualified Opinion------Unqualified Opinion
Auditor --PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian (Special General Partnership)------Ernst & Young Huaming (Special General Partnership), Ernst & Young------Ernst & Young Huaming (Special General Partnership), Ernst & Young

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg